Akrevia Therapeutics, a Cambridge, Mass.-based biopharmaceutical company focused on developing tumor-targeted immuno-oncology therapeutics, closed a $30m Series A financing.
The round was led by F-Prime Capital Partners and Atlas Venture.
The company intends to use the funds to accelerate the development of its pipeline and proprietary Aklusion® platform.
Led by Tim Clackson, Ph.D., President and Head of R&D, and Nessan Bermingham, Ph.D., Executive Chairman, Akrevia Therapeutics focuses on developing highly-potent, targeted immuno-oncology therapeutics. The company’s proprietary Aklusion platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of immune-activating proteins that can be safely delivered. Akrevia is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer.
Additional leadership includes:
- Ronan O’Hagan, Ph.D., who formerly co-led the oncology discovery program at Merck, as SVP of Discovery, and
- Margaret Karow, Ph.D., formerly of Amgen and Regeneron, as SVP of Preclinical Development.